乳腺病灶手术切除后活检部位标记物残留:与残留恶性肿瘤的相关性
本回顾性研究纳入30例乳腺病灶切除后首次术后钼靶报告活检部位标记物(BSM)残留的患者,评估残留恶性肿瘤的频率。恶性索引病理患者残留恶性肿瘤频率高于非恶性索引病理患者(39% vs 0%,p = .02)。结论认为残留BSM与恶性索引病灶相关时残留恶性肿瘤风险较高,首次术后钼靶不足以排除残留恶性肿瘤。
要点
- 恶性索引病理患者残留BSM时残留恶性肿瘤频率为39%(7/18),非恶性索引病理患者为0%(0/12),差异有统计学意义(p = .02)。
- 恶性索引病理患者中,初始手术标本无恶性肿瘤者残留恶性肿瘤频率为80%(4/5),有恶性肿瘤者为23%(3/13),差异有统计学意义(p = .047)。
- 术后首次钼靶阳性判读(BI-RADS 4类或6类)在有和无残留恶性肿瘤患者间无显著差异(57% [4/7] vs 55% [6/11],p > .99)。
核心结论
- 与恶性索引病灶相关的残留BSM患者存在残留恶性肿瘤的较高风险。
- 首次术后钼靶不足以排除残留恶性肿瘤。
- 与恶性索引病灶相关的残留BSM应被视为可疑残留恶性肿瘤,此时针对残留BSM及时追加组织取样是合理的,因为恶性肿瘤概率大于2%。
- 非恶性索引病灶残留BSM的患者,主动监测是合理的管理策略。
研究设计与样本
- 回顾性研究,纳入30例患者(中位年龄59岁),于2015年8月至2022年4月间接受临界、高危或恶性乳腺病灶手术切除。
- 纳入条件为影像引导下空心针活检(CNB)后、术前影像引导定位技术充分,且首次术后钼靶报告描述残留未迁移BSM。
- 提取电子病历数据;索引病理(CNB和初始手术切除)分类为恶性或非恶性。
- 残留恶性肿瘤的存在需后续组织取样病理确认;无残留恶性肿瘤需2年良性影像随访确认。
- 13例标本钼靶由外科医生术中判读、放射科医生后续判读,17例由放射科医生实时判读。
诊断标准与关键数值
- 残留恶性肿瘤频率在恶性索引病理患者为39%(7/18),非恶性索引病理患者为0%(0/12),p = .02。
- 恶性索引病理患者中,残留恶性肿瘤频率在初始手术标本无恶性肿瘤者为80%(4/5),有恶性肿瘤者为23%(3/13),p = .047。
- 恶性索引病理患者中,首次术后钼靶阳性判读(BI-RADS 4类或6类)频率在有残留恶性肿瘤者为57%(4/7),无残留恶性肿瘤者为55%(6/11),p > .99,无显著差异。
临床应用与阅片要点
- 与恶性索引病灶相关的残留BSM应视为可疑残留恶性肿瘤。
- 在此情形下,针对残留BSM及时追加组织取样是合理的,因为恶性肿瘤概率大于2%。
- 非恶性索引病灶残留BSM的患者,主动监测是合理的管理策略。
- 首次术后钼靶不足以排除残留恶性肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Biopsy site markers (BSMs) placed during image-guided core needle biopsy (CNB) are typically targeted for surgical excision, along with the breast imaging abnormality. Retained BSMs raise concern of incomplete resection of the breast abnormality. OBJECTIVE. The purpose of our study was to assess the frequency of residual malignancy in patients with retained BSMs identified on the initial mammography performed after breast lesion surgical excision. METHODS. This retrospective study included 30 patients (median age, 59 years) who underwent surgical resection between August 2015 and April 2022 of a borderline, high-risk, or malignant breast lesion after CNB and technically adequate preoperative image-guided localization, in whom the initial postoperative mammography report described a retained nonmigrated BSM. EMR data were extracted. The index pathology from CNB and initial surgical resection was classified as malignant or nonmalignant. The presence of residual malignancy after initial surgical resection required pathologic confirmation from subsequent tissue sampling; the absence of residual malignancy required 2 years of benign imaging follow-up. RESULTS. Thirteen specimen radiographs were interpreted intraoperatively by a surgeon with later radiologist interpretation, and 17 underwent real-time radiologist interpretation. Eighteen patients had malignant index pathology from the initially resected lesion. The frequency of residual malignancy on subsequent follow-up after initial surgical resection was higher in patients with malignant than nonmalignant index pathology (39% [7/18] vs 0% [0/12], respectively; p = .02). Among patients with malignant index pathology, the frequency of residual malignancy was higher in those without, than with, malignancy in the initial surgical specimen (80% [4/5] vs 23% [3/13]; p = .047). Also in these patients, the frequency of a positive interpretation of the initial postoperative mammography (BI-RADS category 4 or 6) was not significantly different between those with and without residual malignancy (57% [4/7] vs 55% [6/11]; p > .99). CONCLUSION. Patients with retained BSMs associated with malignant index lesions are at substantial risk of having residual malignancy. Initial postoperative mammography is not sufficient for excluding residual malignancy. CLINICAL IMPACT. Retained BSMs associated with index malignancy should be considered suspicious for residual malignancy. In this scenario, timely additional tissue sampling targeting the retained BSM is warranted, given the greater-than-2% chance of malignancy. Active surveillance is a reasonable management strategy in patients with retained BSMs from nonmalignant index lesions.
引用
- Langman EL, Johnson KS, Dinome ML, et al. Retained Biopsy Site Markers After Breast Lesion Surgical Resection: Associations With Residual Malignancy. AJR Am J Roentgenol. 2023. PMID: 37646391. doi:10.2214/AJR.23.29670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。